STOCKCHASE

His model price is $26.88, which is a 22% positive differential. Yielding 4%. This happens to be one that has valuation and yield together, which is great. His target would be about $26.

2012-01-04

DON'T BUY

18.450

Hap (Robert) Sneddon FCSI

Pharmaceutical space is tough. Lipitor is a drug that is going off-patent which will reduce their income.

2011-11-23

BUY

18.960

Barry Schwartz

The 3 sectors hated sectors in the US are financials, healthcare and technology. They have done a lot of smart things recently. They increased the dividend and announced a share buyback. Valuation is quite cheap and he is looking at this one.

2011-11-21

HOLD

19.870

A good space. Defensive name. Prefers JNJ. Seeing higher lows this year. Could come down to a higher low. Ranked 5th on his list. Would hold it.

2011-11-15

SELL

19.360

The whole pharma business is challenged. PFE is predicting lower revenues next year. Management is talking about breaking up the company. With Lipitor patent expiring, he would just sell it.

2011-10-24

DON'T BUY

18.820

Christine Poole

Suffering from loosing their patent on lipitor. Will be a pullback on earnings. Trying to reassess their businesses and potentially spinning some off. Not a big fan of large cap Pharma. Prefers diversified health care companies like Abbot.

2011-10-12

TOP PICK

17.450

Debt rating cut but it doesn’t matter to him. They all have the patent cliff. He likes that they bought Wyeth who have a lot of drugs on patent. People say PFE is too big to make a difference if a new drug comes along so they are shrinking the company. Big, safe dividends.

2011-09-23

DON'T BUY

19.360

Lipitor is coming off patent and accounts for a boat 20% of their revenues. Sales are expected to drop about 5% next year.

2011-07-28

WEAK BUY

20.070

Richard Fogler

Largest drug company in the world. Good pipeline, but they have been paring it down to focus on new drugs. Prefers Teva.

2011-07-22

BUY on WEAKNESS

20.240

Mohsin Bashir

This would be his 2nd choice after Eli Lilly (LLY-N). Facing the issue of a patent cliff where drugs are coming off patent. Has about 4 drugs expecting to move into phase 3 trials. Very attractive multiple. Good dividend yield.

2011-06-16

HOLD

20.890

Laura Wallace

Largest global pharma. Likes it. Whole pharma sector has been suffering from a lack of new block buster drugs. This one is facing the expiration of the patent on their Lipitor drug but this is already reflected in the stock price. Have some very promising drugs in phase 2 and 3 clinical trials. Stock is not expensive and has a 4% yield.

2011-05-12

DON'T BUY

20.630

Has done well lately on the potential of it breaking up and selling off the pieces. The difficulty in the whole pharma sector is that it is tough to grow.

2011-04-27

BUY

20.290

Likes this one especially because they have announced they are going to downsize the company and shareholders will be rewarded for that. Selling a capsule manufacturing company for $2.5 billion.

2011-04-06

DON'T BUY

20.350

Lorne Steinberg

Drug sector is all suffering from same thing – drugs coming off patent faster than entering the pipeline. Are trying to rebuild themselves. They are all trying to get their costs down.

2011-03-25

BUY

20.300

Thinks it is turning around. Very good yield. Have a difficult time with some of the blockbuster drugs coming off patent.

2011-03-24

Comment

19.760

Don Reed

Are breaking themselves up after a string of acquisitions. He sees this happening. Want to get rid of their generics.

2011-03-15

TOP PICK

19.240

New CEO is changing the company compared to the other pharmas. R&D has been a big pit for all companies and he is cutting this back. Will be basically be cutting the company into smaller parts.

2011-02-28

DON'T BUY

18.828

Karl Berger

Not keen on the big pharma complex at this stage. This one in particular has had struggles with their pipeline. There are better ways to play the health care space.

2011-02-11

PAST TOP PICK

18.110

(A Top Pick Feb 3/10. Down 0.29%.) Model price is $29.91, an upside of 62%. Good dividend. His earnings estimate shows $2.22. Still a Buy.

2011-01-05

Comment

17.610

A lot of the pharmaceuticals have been in the doldrums for a long time. Large dividend yield and cheap on a PE basis but their large blockbuster drugs are coming off patent.

2010-12-23

WEAK BUY

17.560

Coming out of the recession pharmaceuticals have not recovered to 2007 levels. Market worries about Obamacare and generics impact on branded drugs. Also worried about FDA approval process.. Also subject to litigation. Tremendous amount of cash and trading at very low multiples. Looking at this.

2010-12-22

Comment

17.030

Gavin Graham

Have had a lot of issues and the CEO has left. Has been an abysmal investment over the last 5-10 years. Decent dividend. What do they do when Lipitor goes off patent mid 2011? Their acquisition of Wyeth gives them a decent stream of products. Trading at 8X earnings. Everybody hates it so maybe it’s worth looking at.

2010-12-17

HOLD

17.220

Rick Stuchberry

Looked at it a couple of times. Lots of cash, good name, but he has never been able to pull the trigger. He thinks you need to let it go up a bit and increase volume, but if you own it, you get paid to wait.

2010-12-16

DON'T BUY

16.798

Karl Berger

Concerned with risk from generic competition to the big pharmas. Prefers Teva (TEVA-Q). The big pharmas will continue to struggle because of this.

2010-11-19

DON'T BUY

16.829

Lost its ability to grow because of its size. Lipitor represents 20% and it goes off patent next year so they’ll be competing with generics.

2010-11-10

PAST TOP PICK

16.829

(Top Pick Nov 16/09, Down 5%) Drug stocks have been out of favour. Drug stocks bottomed earlier this year. Have a number of drugs coming off patent. Dividend investors have identified drug companies as targets.

2010-11-09

BUY

17.051

(Top Pick Nov 30/09, Down 4.77%) $28.23 model price. 64% upside. He keeps on buying it. Held for 4 years in his fund. There is value there and major consolidation going on there. It’s a changing landscape – they are getting together with generics.

2010-11-08

DON'T BUY

17.660

The whole pharma business is somewhat challenged. They spend lots developing a drug and then a few years later it goes Generic. One drug is a quarter of their business but it goes Generic in 2011. There are better places to go. This is more of a defensive stock. Would prefer a hybrid that just has pharma as a part of the their business.

2010-10-20

PAST TOP PICK

17.231

Colin Stewart

(A Top Pick Oct 8/09. Up 5.36%.) Still likes.

2010-10-05

HOLD

16.330

Has been a long-term sufferer. Product outlook is much better since the merger. They have started to increase their dividend again. This is a dividend stock with some upside potential.

2010-09-07

DON'T BUY

15.060

Barry Schwartz

(Market Call Minute) Doesn’t buy US stocks.

2010-05-25

DON'T BUY

16.600

Pharma model, i.e. spending a boatload of money developing drugs and getting it into market, is really stumbling. Then the clock starts ticking with generics coming in down the road. Lipitor expires next year.

2010-04-21

DON'T BUY

17.070

Don Lato

Their big drug Lipitor comes off patent next year, which will be a lot of revenue that will be difficult to replace. Have an “OK” pipeline. Because of their size, it takes a huge blockbuster drug to turn the needle to a positive direction.

2010-04-14

HOLD

17.290

John Zechner

$2 in annualized earnings. Very cheap stock. Doesn't have the growth that it used to. Have global growth and is a beneficiary of the decline in the US$.

2010-04-12

BUY

17.140

Stan Wong

Like it for its dividend of about 4.1%. Very high cash flow. Have diversified their product line with the acquisition of Wyeth.

2010-04-08

BUY on WEAKNESS

16.900

Benj Gallander

(Market Call Minute) If it came down a little bit be would be much more interested.

2010-04-05

DON'T BUY

17.390

Great company with a great yield and trading at a very low multiple. Pharmaceutical industry made so much money on their blockbuster drugs but that dried up. This company has made some good acquisitions and are continuing to cut costs. Pipeline is reasonable but you're not going to see the big blockbuster drugs in the next several years.

2010-03-25

DON'T BUY

17.610

Barry Schwartz

Wouldn't own any US pharmaceutical companies. Research pipeline cupboard is really bare. Doesn't see any growth. A lot of generic competition.

2010-03-24

DON'T BUY

17.540

Don Lato

Pfizer (PFE-N) and Merck (MRK-N) are pretty fully priced at current levels. Growth prospects are not that great, especially with a lot of drugs coming off patent. Multiple looks attractive and dividend looks okay but there are better places to go in pharmaceuticals. Prefers Abbott Labs (ABT-N).

2010-03-23

SELL

17.670

One of the mega pharmas that is having trouble getting traction because it is so large. They have a problem with one of their large drugs (25% of business) coming off patent within the next year. He would look elsewhere. J&J, Abbot, are better picks.

2010-02-17

TOP PICK

18.620

Model price of $29.40, a 53% positive differential.

2010-02-03

HOLD

18.620

Don Vialoux

Just reported lower-than-expected earnings. Chart shows a strong upward trend so technically it still looks good. Usually healthcare stocks do very well from July to October.

2010-02-03

PAST TOP PICK

18.630

(A Top Pick Jan 27/09. Up 25.12%.) Likes the outlook for drug stocks. Still a Buy.

2010-01-28

BUY

19.380

Jeff Black

Have their challenges with patent expiries but a huge global player with very good exposure to emerging markets. Reasonable dividend. 3.7% yield.

2010-01-14

DON'T BUY

19.210

Loss of their Lipitor patent in 2011 (25% of revenues) is priced into the stock but this is a problem with all Pharma plays. Patent expirations is hugely punitive. (See Top Picks.)

2010-01-13

PAST TOP PICK

18.580

(A Top Pick Jan 27/09. Up 17.5%.) The world hated pharmaceutical stocks but started to like them more. All the major pharmas have patents coming off in the next 5 years. This is already built into the price. Companies have all built up big cash reserves.

2009-12-23

BUY

18.290

Ara Nalbandian

Biovail is the only Canadian equivalent. He likes the industry. Concern as patents expire. Market has valued this concern into the price. Continue to generate cash flow. Prefers Merck.

2009-12-15

TOP PICK

17.940

US healthcare stocks were ignored until recently. Recently completed its acquisition of Wyeth, which gives them a new product pipeline. 3.7% yield.

2009-11-16

DON'T BUY

16.960

David Driscoll

The issue here is Lipitor patents coming off in 2010 and they have to fill the product pipeline with something that is going to be a blockbuster. Question that they can use their cash horde effectively to fill the R&D pipeline, get new products to market and get their profits up. (See Top Picks.)

2009-11-06

BUY

16.930

Stan Wong

About the 50-day and 200-day moving averages and is continuing to climb. 3.7% dividend and they are due for an increase.

2009-11-04

DON'T BUY

17.260

Big pharmaceutical has 3 major problems. 1) Cost of developing new drugs keeps going up and up. 2) When you do find a new drug there are chances of killing/harming people accidentally. 3) When you do find a new drug that works, the generics come after you.

2009-10-27

SELL

17.560

Benj Gallander

(Market Call Minute) Interesting play. They’ve just done a huge deal. Corporations that do huge take-overs usually take a while to swallow the company.

2009-10-22

WATCH

17.660

Christine Poole

A lot of their drugs were coming off patent, which is why they bought Wyeth, which has a strong portfolio of women's healthcare. With this acquisition closing, she would expect a lot of integration savings and cutting of costs. She would like more detail on this.

2009-10-15

BUY

16.780

Although they have drugs coming off patent over the next few years, they are acquiring wyeth and they have some promising new drugs.

2009-10-13

TOP PICK

16.700

Colin Stewart

Pharmaceutical industry has been very much out of favour. Likes the long-term play in pharmaceuticals with the aging population and demographics. Recently bought Wyeth (WYE-N) and expecting a lot of synergies from this. Trades at 8.5X earnings with almost 4% dividends.

2009-10-08

BUY

16.250

Good performer in the last 6 to 7 months. Decent yield. Problem with all major pharma stocks are the products coming off patent requiring new avenues for growth. Acquired Wyeth (WYE-N), which has fewer drugs coming off patent and more coming on line. (Also owns Teva for their generic drugs.)

2009-09-11

DON'T BUY

16.340

Peter Brieger

This will depend on what the US president comes up with on a healthcare plan. Until that is resolved all the drug stocks will be under pressure.

2009-09-10

DON'T BUY

16.390

Andrew Guy, CFA

Largest drug company globally. Very strong number of products but along with most of the big pharmaceutical companies there are a large number of drugs that come off patent. About 25% of their earnings comes from one drug, Lipitor and when it comes off patent it will have a big effect on their earnings. There are better places to be.

2009-09-04

DON'T BUY

16.800

Karl Berger

This is not the one to bet on in this sector. Very cheap, up for a reason. Drug pipeline is not impressive. Have patent issues. (See Top Picks.)

2009-08-25

Comment

16.370

Ara Nalbandian

Recently started buying through selling Put options, which would require him to Buy (e.g. at $16). Tide is turning on the sector and he likes it very much. Risks are healthcare reform and patent expirations.

2009-08-19

DON'T BUY

16.620

There will continue to be pressure on prices. Also US government is litigation friendly, which can hit them with 1) injury related suits and 2) patent infringement.

2009-07-27

HOLD

14.590

Gavin Graham

Reflects all the bad news that Lipitor will be going going off patent in a couple of years and its drug pipeline is absolutely barren. In the meantime you get paid 6.5%. Pretty cheap.

2009-07-07

TOP PICK

14.570

Kevin O'Leary

Thinks the pharmaceutical sector will start to do quite well in the next 2 years. It is so negative now in terms of what the government wants to do but historically they have never been able to cut the price of drugs. You are getting 5% to wait.

2009-07-06

DON'T BUY

14.760

Charles Lannon

Not a fan of big cap pharma and hasn't been for some time. One of the most difficult business models to operate. Regulatory issues are so difficult to overcome between patent expiries and increasingly stringent health regulations and registration processes. (See Top Picks.)

2009-06-12

SELL

14.640

Matthew McCall

The major pharmaceuticals are not on his top list. Bioteches are where you are going to see innovations. They are the ones coming out with the new drugs and have a better pipeline.

2009-06-04

DON'T BUY

13.910

Just doesn't seem to be up to right itself. Spinning off a lot of cash but its size limits it from growing.

2009-05-06

DON'T BUY

13.340

Getting killed by generics. They get sued when they hurt people. Government won't stand up for them when generics can provide health care at a fraction of the price. Prefer TEVA-O

2009-04-14

DON'T BUY

13.620

Brett Hryb

Has been a difficult stock. Could improve from here however there will be other opportunities in this space you could get more juice from.

2009-03-31

PAST TOP PICK

13.700

(A Top Pick April 10/08. Down 27.8%.) Paired with Teva (TEVA-Q) as his generic company. Down a little because of their intention to purchase Wyath. Cut their dividend but still gives a healthy yield. Good defensive place.

2009-03-30

BUY

14.380

Made a good acquisition of Wyeth. Have created value in previous acquisitions. Cut the dividend while making the deal so the stock price fell. This made a lot of sense. The big issue is whether this will fill a hole in their product line. Reasonable dividend and very good balance sheet.

2009-03-26

DON'T BUY

14.250

David Abella

A former glory growth stock. A lot of healthcare products and there is the issue of aging in America but that is offset by many of their expensive premier drugs going generic. Just cut their dividends. Would prefer other pharmaceutical stocks.

2009-03-18

PAST TOP PICK

13.590

(A Top Pick Feb 27/08. Down 40%.)

2009-02-24

DON'T BUY

14.580

Gavin Graham

Cut the dividend in order to preserve cash to make acquisitions even though their balance sheets is fortress like. Lipitor is coming off patent in a couple of years. Stock has been very disappointing. A "show me" stock.

2009-02-13

HOLD

14.710

Brett Hryb

(Market Call Minute.) Just completing an acquisition.

2009-02-09

HOLD

14.840

At this price it is probably near a low. Made a big acquisition that is scaring everybody. Can't see a lot of downside from here.

2009-02-06

SELL

14.580

David Driscoll

Made a huge bet with their acquisition of Wyeth and the patents are running off. If it doesn't work out they are going to have some very difficult times.

2009-01-30

TOP PICK

15.820

(A Top Pick Jan 7/08. Down 28,2%.) Likes it for its valuation and its recent acquisition of Wyeth, which gets them into biotechnology and vaccines. Cheap on an earnings basis. Over 4% dividend. In a recession, drug stocks do relatively well. Stock has been oversold.

2009-01-27

BUY

17.750

Currently, pharmaceutical stocks are outperforming the market. A good place to hide and to make some money. Yield of 7.2%. Lots of cash.

2008-12-30

TOP PICK

17.360

His model price is $24.87, a 50% upside. $24 billion in cash.

2008-12-16

SELL

16.630

Matthew McCall

Get Out! Sell. Not a fan of pharmaceuticals. Feels innovations will be in biotechnology not pharmaceuticals.

2008-12-15

VAGUE

16.470

Alan Kral , CFA, CIC

Manufactures of the drug lipidore (the most popular cholesterol drug) Their patent is running out in 2011 - 2012 and they are considering walking away and getting into cancer drugs.

2008-12-09

DON'T BUY

15.280

David Burrows

Health care space, specifically drugs and bio pharmaceuticals is interesting but this is not one that he would Buy. Continue to have issues with drugs coming off of patents and relatively low revenue growth. Would prefer something like Gilead Sciences (GILD-Q) or a generic like Teva (TEVA-Q). This is an area where you should have some exposure.

2008-12-01

Comment

16.280

High dividend yield. Cheap because people think there is not much in the pipeline. Lipitor will be going off patent so earnings will drop. Almost like a short-term bond in that you get cash flow from existing drugs that are pretty dependable but not much growth. Sold his holdings about 2 years ago because of lack of growth. Relatively safe but not a lot of upside.

2008-11-14

DON'T BUY

15.830

Have a lot of cash and produce a lot of cash flow. Very high dividend. They cannot seem to get any catalyst for growth. A lot of competition from generic drug companies.

2008-11-12

HOLD

16.740

David Abella

Losing Lipitor in a couple of years but thinks this is priced into the stock. They are doing cost cutting. Pipeline is a little weak. From a historic PE level and dividend it is a very attractive value. However, if the US is to regulate more and put price fixing on drugs, that would definitely be a negative.

2008-10-22

BUY

17.650

Interesting sock. Almost like a bond. Price assumes there will be no significant new drugs so revenue is based on existing drugs until they come off patent. No phase 2 drugs have hit over the last 2 years.

2008-10-07

DON'T BUY

17.810

David Driscoll

Drugs are coming off patent and are they going to be able to replenish the pipeline? Does management have the ability to keep the cash flow chugging along? The market is telling you No. 7% yield but that there is very little else.

2008-09-16

TOP PICK

18.390

Value manager’s dream but never has done anything. He has a model price of $30.26. 66% positive differential.

2008-09-11

DON'T BUY

19.200

Ron Meisels

Trendline and 200-day moving average have been moving down. It has not made a base.

2008-09-03

DON'T BUY

19.080

Owned it about a year ago with a theory that their drugs were worth what the stock price was going at hand you would make money on all the new drugs they developed. The problem is, they haven't developed any new drugs in almost 3 years. Would prefer Merck (MRK-N).

2008-08-27

BUY

19.750

Paul Larson

Worth considering at this price. Very cheap. Double-digit free cash flow yield and very attractive dividend yield. Lipitor will be coming off patent and pipeline of new drugs is relatively thin. Will be lucky to have 0% growth over the next 5 years but over the very long term they will get the pipeline filled.

2008-08-22

DON'T BUY

19.370

David Burrows

Pharmaceutical group is behaving better. This one is less attractive and is facing drugs coming off patent. Prefers others.

2008-08-21

TOP PICK

19.430